The effect of 5% imiquimod cream on C57BL/6 mouse melanoma growth

Korean Journal of Dermatology

Volumn 43, Issue 10, 2005, Pages 1332-1336

  In, Seung Gyun ^a   Lee, Jong Rok ^a   Shin, Jeong Hyun ^a   Choi, Gwang Seong ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

C57BL 6 mouse; Imiquimod; Melanoma; Ultrasound

Indexed keywords

DIMETHYL SULFOXIDE; DRUG VEHICLE; IMIQUIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; CREAM; DRUG EFFECT; EVALUATION; IN VIVO STUDY; INOCULATION; MELANOMA; MOUSE; NONHUMAN; ULTRASOUND;

EID: 29544434098     PISSN: 04944739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jeong EG, Lee JH, Park HJ, Oh ST, Lee JY, Cho BK. A case of actinic keratoses treated with topical imiquimod. Korean J Dermatol 2004;42(9):1201-1204
2. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol 2003;149 (Suppl. 66):37-39
3. Arlette JP. Treatment of Bowen's disease and erythroplasia of Queyrat. Br J Dermatol 2003;149 (Suppl. 66):43-49
4. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004;29:15-21
5. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003;149 (Suppl. 66):66-70
6. Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151:485-488
7. Park JH, Hwang ES, Kim SB, Ahn HH, Kim IH. A case of basal cell carcinoma of the nose successfully treated with 5% imiquimod cream. Korean J Dermatol 2004;42(5):646-649
8. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 2003;149 (Suppl. 66):53-56
9. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003;149 (Suppl. 66):57-58
10. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003;149 (Suppl. 66):59-61
11. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol 2004;140:404-406
12. Ugurel S, Wagner A, Pfohler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002;147:621-624
13. Palamara F, Meindl S, Holemann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004;173:3051-3061
14. Nestle FO, Kerl H. Melanoma, In: Bolognia JL, Jorizzo JL, Rapini RP, et al, editors. Dermatology, 1st ed. London: Mosby, 2003:1789-1811
15. Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol 2004;50:792-796
16. Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2003;149 (Suppl. 66):5-8
17. Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004;9:291-298
18. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004;30:1543-1545
19. Chakrabarty A, Geisse JK. Medical therapies for non-melanoma skin cancer. Clin Dermatol 2004;22:183-188
20. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004;4:9
21. Meyer T, Nindl I, Schmook T, Ulrich C, Sterry W, Stockfleth E. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 2003;149 (Suppl. 66):9-14
22. Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schon M. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004;122:1266-1276
23. Hesling C, D'Incan M, Mansard S, Franck F, Corbin-Duval A, Chevenet C, Dechelotte P, Madelmont JC, Veyre A, Souteyrand P, Bignon YJ. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004;150:761-767
24. Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discov Today 2004;9:670-676
25. Merino G, Kalia YN, Guy RH. Ultrasound-enhanced transdermal transport. J Pharm Sci 2003;92:1125-1137